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Although LysR-type regulators (LTTRs) represent the largest family of
transcriptional regulators in bacteria, the full-length structure of only one
annotated LTTR (CbnR) has been deposited in the PDB. CrgA, a LTTR from
pathogenic Neisseria meningitidis MC58, which is up-regulated upon bacterial
cell contact with human epithelial cells, has been cloned, purified and
crystallized. Crystals of full-length CrgA were obtained after buffer screening
with a thermal shift assay and concentration with 0.2M NDSB-256. Data were
collected from two crystal forms of full-length CrgA belonging to space groups
P212121 and P21, diffracting to 3.0 and 3.8 A˚ resolution and consistent with the
presence of between six and ten and between ten and 20 copies of CrgA in the
asymmetric unit, respectively. In addition, diffraction data were collected to
2.3 A˚ resolution from the selenomethionine derivative of the regulatory domain
of CrgA. The crystals belonged to space group P21 and contained two molecules
in the asymmetric unit.
1. Introduction
The LysR family of transcriptional regulators (LTTRs) were first
reported by Henikoff et al. (1988) and are now known to represent
the largest family of bacterial transcription factors (Pareja et al.,
2006). LTTRs have molecular weights of between 30 and 36 kDa and
comprise an N-terminal DNA-binding domain (65 residues) that
contains a winged helix–turn–helix motif joined by a linker helix
(30 residues) to a C-terminal regulatory domain (200 residues)
that is involved in oligomerization of the protein, typically into
tetramers (Schell, 1993; Lochowska et al., 2001; Ezezika, Haddad,
Neidle et al., 2007; Smirnova et al., 2004; Rosario & Bender, 2005;
Muraoka et al., 2003).
Structural studies of full-length LTTRs have been hampered by
their low solubility and tendency to aggregate (Ezezika, Haddad,
Clark et al., 2007; Smirnova et al., 2004). To date, crystal structures of
only one full-length LTTR, CbnR, have been deposited (Muraoka et
al., 2003). Two crystal forms of CbnR were obtained, both comprising
protein tetramers but differing in the relative orientation of the
subunits. In contrast, several regulatory-domain structures of LTTRs
have been described, including CysB, which was derived from a
chymotryptic fragment (Tyrrell et al., 1997), OxyR (Choi et al., 2001),
BenM, CatM (Ezezika, Haddad, Clark et al., 2007) and Cbl (Stec et
al., 2006), which were produced from C-terminal domain constructs,
and DntR, which was crystallized as a full-length protein but only the
regulatory domain and a small portion of the linker helix were
sufficiently ordered to allow a model to be built (Smirnova et al.,
2004).
CrgA (contact-regulated gene A) is an LTTR from the exclusive
human pathogen Neisseria meningitidis (serogroup B) strain MC58, a
causative agent of bacterial meningitis and septicaemia (Rosenstein
et al., 2001). N. meningitidis is a common commensal, colonizing the
nasopharynx of 8–20% of healthy individuals (Stephens, 2007) and
only rarely causing invasive disease by gaining access to the blood-
stream through penetration of the nasopharyngeal mucosa (Rosen-
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stein et al., 2001). After transmission, in order for successful coloni-
zation the meningococci must overcome the host immune system and
adhere to the nasopharyngeal epithelial cells (Rosenstein et al., 2001;
Stephens, 2007). Adhesion can be viewed as a two-step process.
During initial adhesion, which is a pilus-mediated event, the menin-
gococci attach as microcolonies to the surface of the host cells. Later
in infection, during intimate adhesion, the pili disappear, the micro-
colonies disband and the meningococci become more closely asso-
ciated with the host plasma membrane (Merz & So, 2000). CrgA has
been reported to be induced upon contact of N. meningitidis with
human epithelial cells and in functional assays meningococci lacking
CrgA are unable to undergo intimate adhesion to epithelial cells
(Deghmane et al., 2000, 2002). Like the majority of LTTRs, CrgA is a
dual regulator, activating the expression of the divergently orientated
mdaB (modulator of drug activity) gene while repressing its own
expression (Deghmane & Taha, 2003; Ieva et al., 2005; Schell, 1993).
CrgA has also been shown to bind to the promoter regions of genes
encoding surface-associated proteins (PilC, sia and pilE) and is
shown to down-regulate these genes. Therefore, it appears to play a
role in regulation of the transition between the initial and intimate
stages of adhesion (Deghmane et al., 2002).
CrgA has 299 residues and shares less than 17% (BLASTP and
ClustalW) sequence identity to CbnR and other LTTRs currently
deposited in the PDB. Here, we report the cloning, purification and
crystallization of full-length (FL-CrgA) and regulatory-domain
(RD-CrgA) forms of CrgA. The strategy developed to stabilize
FL-CrgA prior to crystallization is detailed. Preliminary crystallo-
graphic analysis of the data sets collected is presented.
2. Experimental methods and results
2.1. Cloning
Full-length (FL-CrgA) and C-terminal regulatory-domain (RD-
CrgA; residues Glu89–Gly299) constructs of CrgAwere designed for
recombinant expression in Escherichia coli. The crgA gene
(NMB1856) was amplified from genomic DNA (N. meningitidis
MC58) by PCR using KOD Hot Start DNA Polymerase (Merck) and
cloned with In-Fusion technology (Clontech) following the methods
reported by Berrow et al. (2007). The forward primer 50-GGGGA-
CAAGTTTGTACAAAAAAGCAGGCTTCGAAGGAGATAGA-
ACCATGGCACATCACCACCACCATCACGAAATACCGCAA-
GGCGTGTTGAGC and the reverse primer 50-GGGGACCACTTT-
GTACAAGAAAGCTGGGTCTCATTATCCACAGAGATTGTTT-
CCCAGTTCC were used in the construction of the RD-CrgA
expression construct containing a 3C protease-cleavable N-terminal
hexahistidine purification tag with sequence MAHHHHHHSS-
GLEVLFQ#GP (the 3C protease site is shown in bold, with the
cleavage point indicated by an arrow). The forward primer 50-
AGGAGATATACCATGATGAAAACCAATTCAGAAGAACTG-
AC and the reverse primer 50-GTGGTGGTGGTGTTTTCCACA-
GAGATTGTTTCCCAGTTC were used in the construction of the
FL-CrgA expression construct containing a C-terminal His tag with
sequence KHHHHHH. The sequence-verified expression constructs
were tested for soluble expression by semi-automated small-scale
screening on a Bio Robot 8000 (Qiagen) using the protocols of
Berrow et al. (2007).
2.2. Purification
Native and selenomethionine-labelled protein was produced from
E. coli strain B834 using Power Broth and SelenoMet media
(Molecular Dimensions), respectively. Cells were grown in 2 l
cultures at 310 K to an OD600 of 0.6, the temperature was reduced to
293 K and recombinant protein expression was induced by addition
of IPTG to 0.5 mM. The cultures were grown for a further 20 h and
the cells were harvested by centrifugation at 6000g for 15 min. The
cells were lysed in binding buffer (50 mM Tris pH 7.5, 500 mM NaCl,
20 mM imidazole) supplemented with 0.2%(v/v) Tween 20 and an
EDTA-free protease-inhibitor cocktail tablet (Roche) with a Basic Z
Cell Disruptor (Constant Systems). After centrifugation at 24 000g
for 30 min, the cleared lysate was applied onto a 1 ml HisTrap FF
column attached to an A¨KTA Express protein-purification system
(GE Healthcare). The column was washed to a UV (280 nm) baseline
with binding buffer and the protein was eluted with 50 mM Tris pH
7.5, 500 mM NaCl, 500 mM imidazole. The eluate was loaded onto a
16/60 HiLoad Superdex 200 column (GE Healthcare) pre-equili-
brated in 20 mM Tris pH 7.5, 200 mM NaCl or 20 mM citrate pH 5.0,
200 mM NaCl buffer at 277 K. The N-terminal His tag was removed
from RD-CrgA by overnight incubation of the protein with His-
tagged 3C protease (the vector was kindly donated by A. Geerlof,
EMBL, Hamburg) at 277 K. The 3C protease and any uncleaved
protein were removed by passing the sample through a 1 ml HisTrap
FF column. The purified proteins were analysed by SDS–PAGE
(NuPAGE, Invitrogen) and electrospray mass spectrometry (Nettle-
ship et al., 2008). RD-CrgA and FL-CrgA had a high level of purity
(>98%) and mass spectrometry confirmed full selenomethionine
incorporation of the selenomethionine derivative of RD-CrgA.
2.3. Crystallization of RD-CrgA
The selenomethionine derivative of RD-CrgAwas concentrated to
3.9 mg ml1 in 20 mM Tris pH 7.5, 200 mM NaCl, 1 mM TCEP with a
Vivaspin 15 concentrator (Vivascience). Crystallization screening
experiments were performed at 293 K in nanolitre sitting drops
(100 nl protein and 100 nl reservoir) dispensed from a Cartesian
robot onto a 96-well Greiner plate as described by Walter et al.
(2003). RD-CrgA crystallized readily in 61 (12.7%) of the 480
screening conditions tested. The crystals used for data collection were
optimized from 200 mM ammonium acetate, 25%(w/v) polyethylene
glycol 3350, 0.1M bis-Tris pH 5.5 with protein that had been flash-
cooled, stored at 193 K and then thawed, using a drop ratio of 200 nl
protein:100 nl reservoir in conjunction with an Additive Screen
(Hampton Research) optimization protocol as reported by Walter et
al. (2005).
2.4. Thermal shift assay and crystallization of FL-CrgA
In contrast to RD-CrgA, FL-CrgA concentrated in 20 mM Tris pH
7.5, 200 mM NaCl precipitated out of solution at levels above
0.5 mg ml1 and consequently significant amounts of protein were
lost. Therefore, a thermal shift assay, which monitors the thermal
denaturation of a protein, was carried out on FL-CrgA to screen for a
buffer that would stabilize FL-CrgA. The relationship between
protein thermal stability and solubility is not straightforward,
although in general a more stable protein may be less likely to
aggregate (Ericsson et al., 2006). The buffer screen was composed of
solutions containing 50 mM buffer ranging from pH 4.0 to 9.0
(sodium acetate pH 4 and pH 4.4, citrate pH 5 and pH 5.4, cacodylate
pH 6.0 and pH 6.4, HEPES pH 7 and pH 7.4, Tris pH 8.0 and pH 8.4
and CAPSO pH 9) and 0–500 mM NaCl. 50 ml reactions containing
5 mg FL-CrgA, 1 Sypro Orange dye (Molecular Probes) and the
buffer screen were added to white low-profile thin-wall PCR plates
(Abgene). After sealing with a Microseal ‘B’ Film (BioRad), the plate
was centrifuged at 3000g for 2 min. A BioRad DNA Engine Opticon
2 real-time PCR machine with SYBR Green settings was used to
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monitor the fluorescence. The fluorescence was read every 0.5 K
(after 10 s hold) over a temperature range of 293–368 K. The
apparent melting temperature (Tm) of the protein was calculated
using the Opticon Monitor software from the maximum value of the
first derivative curve of the melting curve (Nettleship et al., 2008).
FL-CrgA was significantly more thermally stable in buffers of mid
to lower pH. Varying the concentration of NaCl appeared to be less
critical but increasing concentrations were associated with a small
stabilization effect. In citrate buffer pH 5.0 containing 200 mM NaCl
the apparent Tm of CrgA increased by around 8 K compared with the
original buffer of pH 7.5 (Fig. 1). On the basis of these results, the
protein was concentrated to 2.4 mg ml1 in 20 mM citrate pH 5.0,
200 mM NaCl and crystallization trials were set up. Although the
solubility of CrgA appeared to have improved in this buffer, losses
from precipitation still occurred and significantly no diffracting
crystals grew from these initial trials.
Nondetergent sulfobetaines (NDSBs) have been reported to
prevent aggregation and to increase the solubility of proteins (Vuil-
lard et al., 1995). Therefore, 0.2M NDSB-256 was added to FL-CrgA
to help prevent precipitation during concentration. Under these
conditions, it proved possible to concentrate the protein to
8.2 mg ml1 with minimal losses. Crystallization trials were set up and
FL-CrgA crystallized in 9 (2.3%) of the 384 screening conditions
tested. Crystals from two crystal forms A and B were optimized.
Initial crystals of form A, grown from the original condition of
10%(v/v) 2-methyl-2,4-pentanediol in 0.1M sodium acetate pH 5.0
(Grid Screen MPD, Hampton Research), were small and multiple
(Fig. 2a). Improved crystals were obtained by streak-seeding; seeds
were transferred with a cat’s whisker into 2 ml [1 ml protein + 1 ml
reservoir containing 10%(v/v) 2-methyl-2–4-pentanediol (MPD) in
0.1M sodium acetate pH 5.0] sitting drops pre-equilibrated for
30 min in a Linbro 24-well tissue-culture plate (Fig. 2b). Preliminary
crystals of form B grown from 0.5M ammonium sulfate, 1M lithium
sulfate, 0.1M trisodium citrate pH 5.6 had a cubic morphology but
were visibly layered (Fig. 2c). After streak-seeding the crystals were
single and grew with an elongated pyramid shape (Fig. 2d). Seeds
were transferred as described above into either 200 nl (100 nl protein
+ 100 nl reservoir in a Greiner plate) or 2 ml (1 ml protein + 1 ml
reservoir in a Linbro plate) sitting drops. The reservoir contained
80% of the original condition above and the drops were pre-equili-
brated for 30 min.
2.5. Data collection and processing
Multiple-wavelength anomalous dispersion data were collected
from crystals of the selenomethionine derivative of RD-CrgA on
beamline BM14 at the ESRF (Grenoble, France). The crystals had a
thin plate-like morphology and despite efforts to optimize them
remained comparatively small; the crystals used in the data collection
had overall dimensions of approximately 70  10  5 mm. However,
they diffracted strongly and data sets at three different wavelengths
were collected from a single crystal to 2.8 A˚ resolution. A higher
resolution data set to 2.3 A˚ was collected from a second crystal at a
single wavelength (Table 1). The crystals were flash-cooled in a
cryosolution consisting of 25%(v/v) glycerol and 75%(v/v) reservoir
solution [200 mM ammonium acetate, 25%(w/v) polyethylene glycol
3350, 0.1M bis-Tris pH 5.5] and maintained at 100 K under a stream
of nitrogen gas during data collection.
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Figure 1
Buffer screening of FL-CrgA with a fluorescence-based thermal shift assay. The
melting point (Tm) of FL-CrgA (y axis) was calculated in buffers of pH 4–9 with 0,
100, 200 or 500 mM NaCl.
Table 1
Data-collection and processing statistics for SeMet RD-CrgA.
Values in parentheses are for the last resolution shell.
Crystal I Crystal II
Peak Remote Inflection Peak
X-ray source BM14
Detector MAR 225 CCD
Space group P21 P21
Unit-cell parameters
a (A˚) 51.59 51.64
b (A˚) 65.49 65.58
c (A˚) 63.31 63.50
 () 105.27 105.02
Wavelength (A˚) 0.9780 0.9065 0.9785 0.9795
Resolution range (A˚) 50.0–2.76 (2.86–2.76) 50.0–2.29
(2.37–2.29)
Unique reflections 10553 (1058) 8620 (235) 8096 (167) 15951 (636)
Completeness (%) 99.9 (99.5) 80.8 (22.1)† 75.9 (15.7)‡ 85.8 (34.8)§
Redundancy 7.4 (6.6) 4.0 (1.5) 3.5 (1.3) 4.1 (1.8)
Average I/(I) 20.1 (4.2) 14.1 (3.3) 13.2 (3.8) 18.0 (2.1)
Rmerge} 0.108 (0.422) 0.097 (0.286) 0.097 (0.214) 0.073 (0.299)
d 0 0/†† 2.48 (1.27) 1.38 (0.87) 1.38 (0.91)
† Data were processed into the corner of the detector and are essentially complete to
3.5 A˚. ‡ Data were processed into the corner of the detector and are essentially
complete to 3.8 A˚. § Data were processed into the corner of the detector and are




i jIiðhklÞ  hIðhklÞij=P
hkl
P
i IiðhklÞ. †† As calculated by SHELXC, with data in the resolution ranges
50–8.0 and 5–4.2 A˚, respectively.
Table 2
Data-collection and processing statistics for native FL-CrgA.
Values in parentheses are for the last resolution shell.
Crystal form A Crystal form B
X-ray source ID14-4
Space group P212121 P21
Detector Q315r ADSC CCD
Unit-cell parameters
a (A˚) 104.64 123.17
b (A˚) 119.09 204.99
c (A˚) 250.20 124.80
 () 93.10
Wavelength (A˚) 0.9765 0.9765
Resolution range (A˚) 30.0–3.00 (3.11–3.00) 30.0–3.80 (3.94–3.80)
Unique reflections 52736 (5140) 60401 (5853)
Completeness (%) 83.1† (82.3) 99.6 (97.2)
Redundancy 3.5 (2.7) 3.7 (3.3)
Average I/(I) 14.1 (1.11) 10.4 (4.10)
Rmerge‡ 0.066 (0.774) 0.138 (0.365)
† The 3.56–3.78 A˚ resolution shell is 23.7% complete. ‡ Rmerge =P
hkl
P





Diffraction data for native FL-CrgA were collected on beamline
ID-14.4, ESRF. Crystals of form A were transferred directly from the
drop into a cryosolution consisting of 0.1M sodium acetate pH 5.0,
25%(v/v) MPD, flash-cooled in liquid nitrogen, transported to the
beamline and mounted via the automatic sample changer. A data set
was collected from the largest crystal of approximate dimensions
300 100 30 mm (Fig. 2b) to 3.0 A˚ resolution with 0.5 oscillations.
Although smaller crystals froze well, the freezing of this crystal was
unsatisfactory. Therefore, the data were only 83.1% complete owing
to a lack of usable reflections in the resolution range 3.56–3.78 A˚
from the ice ring. For crystal form B, prior to the drop being fully
opened to the air, perfluoropolyether PFO-X125/03 oil (Lancaster
Synthesis) was added directly to the top of the drop through a small
hole in the film covering the Greiner plate. A crystal was then
transferred out of the drop through the layer of oil into a cold stream
(100 K) of nitrogen gas. A data set was collected to 3.8 A˚ resolution.
Data were processed with DENZO and SCALEPACK from the
HKL-2000 suite (Otwinowski & Minor, 1997). The data-collection
and processing statistics are presented in Table 2.
2.6. Preliminary crystallographic analysis of the CrgA data sets
The RD-CrgA crystals belong to space group P21. Based on
Matthews coefficient calculations, it is most likely that there are two
molecules in the asymmetric unit, with a Matthews coefficient of
2.25 A˚3 Da1 and a solvent content of 45%. The anomalous signal
from the selenomethionines was monitored using the SHELX suite
and although relatively weak, possibly as a result of the presence of
only two methionines in the sequence separated by a single amino
acid, extended to around 4 A˚ (Table 1). FL-CrgA crystal form A
belongs to the primitive orthorhombic space group P212121. The
asymmetric unit is likely to contain between six and ten copies of
FL-CrgA, resulting in a solvent content of between 68 and 47%. A
native Patterson suggests the presence of a pseudo-translation with a
peak at fractional coordinates (0.5, 0.5, 0.1). Crystals of form B were
monoclinic (P21). In this case between ten and 20 molecules are
expected to be present in the asymmetric unit, corresponding to a
solvent content of 73–47%; no pseudo-translation was detected.
3. Summary
Obtaining crystal structures of full-length LTTRs has proved more
challenging than for their regulatory domains and our experience
with CrgA was consistent with this. Thus, purified full-length CrgA
was less soluble and more difficult to crystallize than the C-terminal
regulatory domain, which accounts for two-thirds of the molecule.
The reasons for the poor solubility of full-length LTTRs is not clear
but may relate to the extended linker helix region which joins the
DNA-binding and regulatory domains. Diffracting crystals of the full-
length protein were produced after buffer optimization using a
thermal shift assay and concentration in 0.2M NDSB-256, empha-
sizing the potential benefits of stabilizing ‘problematic’ proteins prior
to crystallization. The protocol employed in this project may be
generally applicable to other full-length LTTRs, aiding the concen-
tration and crystallization of this class of proteins. Structure deter-
mination of RD-CrgA using MAD techniques is ongoing and if
successful would provide a suitable molecular-replacement model for
the subsequent determination of the full-length structure from the
native data that have been collected.
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Figure 2
FL-CrgA crystals before and after optimization by streak-seeding. (a) Initial crystals of crystal formA grown in 10%(v/v) 2-methyl-2,4-pentanediol, 0.1M sodium acetate pH
5 and (b) crystal form A after optimization by streak-seeding. (c) Initial crystals of crystal form B grown in 0.5M ammonium sulfate, 1M lithium sulfate, 0.1M trisodium
citrate pH 5.6 and (d) crystal form B after optimization by streak-seeding.
and ID14-4 at the ESRF for help with data collection. SS was
supported by an MRC studentship.
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